Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg cuts Intertek target but stays bullish

(Sharecast News) - Berenberg has cut its target price for Intertek from 6,000p to 5,700p but kept a 'buy' rating on the testing and laboratories firm, saying the business is showing "solid growth through macro weakness". A trading update from the company last month revealed that organic growth was slower than expected in the first quarter, mainly due to the performance of its Caleb Brett business, which is exposed to global fuel trade volumes, particularly oil.

However, the slowdown is likely only temporary, Berenberg predicts, with industry forecasts pointing to an increase in crude oil volumes over the year.

Elsewhere, growth in Intertek's Industry and Infrastructure markets is expected to accelerate due to improvements in building and construction, while there are no signs of weakness in the consumer products sector.

"We think that Intertek is the most cyclical of the testing, inspection and certification companies that we cover, given its more material reliance on trade volumes than its peers," said analyst Carl Raynsford.

"While we reduce our growth expectations for FY25 due to a softer Q1, we still think that the company can achieve over 5% organic growth this year, with the major headwind coming from FX."

The stock was down 0.9% at 4,744p by 1134.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.